Operative blood salvage Lipectomy by liposuction
Conditions
Interventions
This is a prospective, randomized, controlled, two-arm clinical trial. Twenty adult patients undergoing large-volume liposuction (aspirate volume = 1,000 mL) will be included and randomly assigned (us
and the Control group (n=10), consisting of patients undergoing liposuction via the conventional technique, without blood recovery or reinfusion.
Sponsors
Hospital Agamenon Magalhães - HAM
Hospital Agamenon Magalhães - HAM
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria adopted for this project were patients of both sexes aged 18 to 65 years; clinical indication for large-volume liposuction, with an anticipated aspirate volume of = 1,000 mL; good general health status (ASA class I or II); preoperative hemoglobin = 12 g/dL (women) or = 13 g/dL (men); absence of known coagulopathies or hematological disorders; no use of anticoagulants or antiplatelet agents in the 10 days prior to the procedure; and signed informed consent from the participant
Exclusion criteria
Exclusion criteria: Exclusion criteria included patients with an active infection at any site at the time of surgery; diagnosis of malignant neoplasm; use of immunosuppressants or systemic corticosteroids; hemoglobinopathies, hemolytic anemias, or other erythrocyte disorders; refusal to participate in the study or to sign the informed consent form; pregnancy or breastfeeding; history of previous transfusion reactions; associated surgeries that could contaminate the surgical field (concomitant gastrointestinal, urological, or gynecological procedures); and an aspirated volume of less than 1,000 mL at the end of the procedure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| assess microbiological safety via fluid culture and red blood cell integrity by measuring free corpuscular hemoglobin and hematocrit in the salvaged blood, as well as to map the patient's systemic inflammatory response (C-reactive protein and erythrocyte sedimentation rate). Such evidence will provide the necessary laboratory support to confirm that there is no difference in inflammatory markers among patients undergoing red blood cell salvage, thereby suggesting the feasibility of its routine use in new plastic surgery scenarios | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcomes are expected | — |
Countries
BR
Contacts
Public ContactLuiz Felipe Fernandes Vieira
Hospital Agamenon Magalhaes
Outcome results
None listed